PIRAMAL PHARMA Financial Statement Analysis
|
||
|
The Revenues of PIRAMAL PHARMA have increased by 3.87% YoY .
The Earnings Per Share (EPS) of PIRAMAL PHARMA has decreased by Negative YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
PIRAMAL PHARMA Last 5 Annual Financial Results
[BOM: 543635|NSE : PPLPHARMA]
| Consolidated | Mar2023 | Mar2022 | Mar2021 |
|---|---|---|---|
| Revenues | ₹6,559 Cr | ₹6,315 Cr | ₹6,315 Cr |
| Expenses | ₹5,609 Cr | ₹4,887 Cr | ₹4,887 Cr |
| Operating Profit (Excl OI) | ₹950 Cr | ₹1,428 Cr | ₹1,428 Cr |
| Other Income | ₹276 Cr | ₹164 Cr | ₹164 Cr |
| Interest | ₹198 Cr | ₹163 Cr | ₹163 Cr |
| Depreciation | ₹586 Cr | ₹545 Cr | ₹545 Cr |
| Profit Before Tax | ₹485 Cr | ₹949 Cr | ₹949 Cr |
| Profit After Tax | ₹376 Cr | ₹835 Cr | ₹835 Cr |
| Consolidated Net Profit | ₹376 Cr | ₹835 Cr | ₹835 Cr |
| Earnings Per Share (Rs) | ₹-1.56 | ₹3.17 | ₹8.40 |
| PAT Margin (%) | -2.30 | 5.15 | 13.22 |
| ROE(%) | -2.77 | 6.11 | 14.90 |
| ROCE(%) | 1.95 | 7.10 | 13.06 |
| Total Debt/Equity(x) | 0.81 | 0.60 | 0.52 |
Key Financials |
||
| Market Cap | : | ₹ 20,419.0 Cr |
| Revenue (TTM) | : | ₹ 8,171.2 Cr |
| Net Profit(TTM) | : | ₹ -41.7 Cr |
| EPS (TTM) | : | ₹ -0.3 |
| P/E (TTM) | : | - |
| Industry Peers & Returns | 1W | 1M | 1Y |
| PIRAMAL PHARMA | 2.9% | 9.1% | 105.8% |
| SUN PHARMACEUTICAL INDUSTRIES | 0.7% | -4.8% | 57.3% |
| CIPLA | 1.9% | -2.4% | 42.6% |
| DR REDDYS LABORATORIES | -5.4% | -4.1% | 20% |
| ZYDUS LIFESCIENCES | 1.3% | 0.5% | 87.4% |
| DIVIS LABORATORIES | 0.1% | 3% | 12.1% |
| MANKIND PHARMA | -1.7% | -7.8% | 57.2% |
| TORRENT PHARMACEUTICALS | -0.5% | 1% | 57.7% |
| LUPIN | 4.8% | 5.2% | 115.9% |
PIRAMAL PHARMA Revenues
[BOM: 543635|NSE : PPLPHARMA]
| Y-o-Y | 3.87 % |
| 5 Yr CAGR | 1.92 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2023 | ₹6,559 Cr | 3.87 | |
| Mar2022 | ₹6,315 Cr | 0.00 | |
| Mar2021 | ₹6,315 Cr | - | |
PIRAMAL PHARMA Operating Profit
[BOM: 543635|NSE : PPLPHARMA]
| Y-o-Y | -33.50 % |
| 5 Yr CAGR | -18.45 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2023 | ₹950 Cr | -33.50 | |
| Mar2022 | ₹1,428 Cr | 0.00 | |
| Mar2021 | ₹1,428 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -35.96 % |
| 5 Yr CAGR | -19.97 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2023 | 14.48% | -35.96 | |
| Mar2022 | 22.61% | 0.00 | |
| Mar2021 | 22.61% | - | |
PIRAMAL PHARMA Profit After Tax
[BOM: 543635|NSE : PPLPHARMA]
| Y-o-Y | -54.98 % |
| 5 Yr CAGR | -32.90 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2023 | ₹376 Cr | -54.98 | |
| Mar2022 | ₹835 Cr | 0.00 | |
| Mar2021 | ₹835 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2023 | -2.3 % | Negative | |
| Mar2022 | 5.15 % | -61.04 | |
| Mar2021 | 13.22 % | - | |
PIRAMAL PHARMA Earnings Per Share (EPS)
[BOM: 543635|NSE : PPLPHARMA]
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2023 | ₹-1.56 | Negative | |
| Mar2022 | ₹3.17 | -62.26 | |
| Mar2021 | ₹8.40 | - | |
PIRAMAL PHARMA Return on Capital Employed (ROCE)
[BOM: 543635|NSE : PPLPHARMA]
| Y-o-Y | -72.54 % |
| 5 Yr CAGR | -61.36 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2023 | 1.95% | -72.54 | |
| Mar2022 | 7.1% | -45.64 | |
| Mar2021 | 13.06% | - | |
PIRAMAL PHARMA Share Price vs Sensex
| Current Share Price | : | ₹154.4 |
| Current MarketCap | : | ₹ 20,419.0 Cr |
| Updated EOD on | : | May 13,2024 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| PIRAMAL PHARMA | 2.9% |
9.1% |
105.8% |
| SENSEX | -1.5% |
-2.6% |
17.8% |
PIRAMAL PHARMA related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| S&P BSE 500 | -1.6% | -1.5% | 32.1% |
| S&P BSE ALLCAP | -1.7% | -1.5% | 33.7% |
| S&P BSE HEALTHCARE | -1.8% | -1.5% | 51% |
| S&P BSE 400 MIDSMALLCAP | -2.4% | -0.4% | 51.5% |
| S&P BSE MIDSMALLCAP | -2.5% | -0.5% | 55.6% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY 500 | -1.7% | -1.5% | 33% |
| NIFTY500 MULTICAP 50:25:25 | -2.1% | -1.3% | 40.3% |
| NIFTY MID SMALL400 | -2.3% | -0.5% | 53.9% |
| NIFTY SMALLCAP250 | -3.6% | -1.5% | 57.4% |
| NIFTY SMALLCAP 50 | -3.9% | -1.7% | 66.4% |
You may also like the below Video Courses
FAQ about PIRAMAL PHARMA Financials
How the annual revenues of PIRAMAL PHARMA have changed ?
The Revenues of PIRAMAL PHARMA have increased by 3.87% YoY .
How the Earnings per Share (EPS) of PIRAMAL PHARMA have changed?
The Earnings Per Share (EPS) of PIRAMAL PHARMA has decreased by Negative YoY .
Check out Intrinsic Value of Peers of PIRAMAL PHARMA
Compare Stock Analytics of Peers of PIRAMAL PHARMA
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
